Zadavotide guraxetan

Other

Also known as FPI-2265, AZD2265

Phase 3underway

Evidence outlook · registrational

Metastatic Castration-Resistant Prostate Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-06-04.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Metastatic Castration-Resistant Prostate Cancer
NCT07611110 · AstraZeneca
2026-05-04 – 2030-06-06 · Metastatic Castration-resistant Prostate Cancer
What this study did
Phase 2 (3)
Metastatic Castration-Resistant Prostate Cancer
NCT06402331 · Fusion Pharmaceuticals Inc.
2024-03-05 – 2031-01-23 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT06909825 · Fusion Pharmaceuticals Inc.
2025-02-26 – 2027-05 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT05219500 · Fusion Pharmaceuticals Inc.
2021-12-16 – 2026-07-31 · Metastatic Castration Resistant Prostate Cancer
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT07590934 · AstraZeneca
2026-06-03 – 2029-09-25 · Metastatic Prostate Cancer
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Metastatic Castration-Resistant Prostate Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zadavotide Guraxetan: this drugPhase 3Radioconjugate (actinium-225)PSMAnot yet gradedNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Partial signalNo reviewed efficacy summary in this indication
TalazoparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
225Ac-PSMA-617
Phase 3(overall)
Radioligand Therapy (actinium-225)PSMA
not yet graded(overall)
No reviewed efficacy summary in this indication
Elfetabart DrozuntecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
FluzoparibPhase 3Small moleculePARP (poly ADP-ribose polymerase), specifically PARP-1not yet gradedNo reviewed efficacy summary in this indication
HRS-4357Phase 3UndisclosedPSMAnot yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
MevrometostatPhase 3Small moleculeEZH2not yet gradedNo reviewed efficacy summary in this indication
OpevesostatPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
PasritamigPhase 3Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
LuxdegalutamidePhase 2Small moleculeAndrogen receptor, Androgen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
HRS-1738
Phase 1/2(overall)
UndisclosedPSMA
not yet graded(overall)
No reviewed efficacy summary in this indication
SHR-4394
Phase 1/2(overall)
Antibody–drug conjugatePSMA
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-969Phase 1UndisclosedPSMA / STEAP1not yet gradedNo reviewed efficacy summary in this indication
AKY-2519Phase 1RadiopharmaceuticalB7-H3-targeted radioligand therapynot yet gradedNo reviewed efficacy summary in this indication
BPX-601Phase 1Cell therapyPSCAnot yet gradedNo reviewed efficacy summary in this indication
RG6852
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zadavotide guraxetan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2026-12-23 · NCT06402331 · CT.gov ↗
What to watch
2027 (1)
May 2027 (1)
Phase 2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2027-05 · NCT06909825 · CT.gov ↗
What to watch
2029 (2)
June 2029 (1)
Phase 3Metastatic Castration-Resistant Prostate CancerRecruiting
Est. primary completion 2029-06-04 · NCT07611110 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1/2Metastatic Prostate CancerRecruiting
Est. primary completion 2029-09-25 · NCT07590934 · CT.gov ↗
What to watch

See the full readout calendar ↗